Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Ovarian Neoplasms

  Free Subscription


1 BMC Cancer
1 Cancer
1 Eur J Obstet Gynecol Reprod Biol
3 Gynecol Oncol
1 Histopathology
1 Int J Cancer
1 Int J Gynaecol Obstet
1 Int J Oncol
1 Oncogene
1 Oncol Rep
1 PLoS Genet

  Retrieve available abstracts of this week’s articles:
HTML format
Text format
Single Articles

    BMC Cancer

  1. JIA SZ, Zhang JJ, Liang ZY, Yang JJ, et al
    Safety and fertility outcomes after the conservative treatment of endometrioid borderline ovarian tumours.
    BMC Cancer. 2018;18:1160.
    PubMed     Text format     Abstract available


  2. BAST RC JR, Matulonis UA, Sood AK, Ahmed AA, et al
    Critical Questions in Ovarian Cancer Research and Treatment: Report of an American Association for Cancer Research Special Conference.
    Cancer. 2019 Mar 5. doi: 10.1002/cncr.32004.
    PubMed     Text format     Abstract available

    Eur J Obstet Gynecol Reprod Biol

  3. BASTU E, Onder S, Demiral I, Ozsurmeli M, et al
    Distinguishing the progression of an endometrioma: Benign or malignant?
    Eur J Obstet Gynecol Reprod Biol. 2018;230:79-84.
    PubMed     Text format     Abstract available

    Gynecol Oncol

  4. SON JH, Kim J, Shim J, Kong TW, et al
    Comparison of posterior rectal dissection techniques during rectosigmoid colon resection as part of cytoreductive surgery in patients with epithelial ovarian cancer: Close rectal dissection versus total mesorectal excision.
    Gynecol Oncol. 2019 Mar 4. pii: S0090-8258(19)30139.
    PubMed     Text format     Abstract available

  5. MERT I, Kumar A, Torres D, Huang Y, et al
    Should mucosal bowel invasion in ovarian cancer be assigned to FIGO stage IV disease?
    Gynecol Oncol. 2019 Mar 2. pii: S0090-8258(19)30128.
    PubMed     Text format     Abstract available

  6. TIMMERMANS M, van der Hel O, Sonke GS, Van de Vijver KK, et al
    The prognostic value of residual disease after neoadjuvant chemotherapy in advanced ovarian cancer; A systematic review.
    Gynecol Oncol. 2019 Feb 27. pii: S0090-8258(19)30129.
    PubMed     Text format     Abstract available


  7. DARB-ESFAHANI S, Kolaschinski I, Trillsch F, Mahner S, et al
    Morphology and tumour-infiltrating lymphocytes in high-stage, high-grade serous ovarian carcinoma correlated with long-term survival.
    Histopathology. 2018;73:1002-1012.
    PubMed     Text format     Abstract available

    Int J Cancer

  8. ZHANG C, Wang X, Anaya Y, Parodi L, et al
    Distinct Molecular Pathways in Ovarian Endometrioid Adenocarcinoma with Concurrent Endometriosis.
    Int J Cancer. 2018 Aug 28. doi: 10.1002/ijc.31768.
    PubMed     Text format     Abstract available

    Int J Gynaecol Obstet

  9. SOOKRAM J, Zheng A, Linden KM, Morgan AB, et al
    Epigenetic therapy can inhibit growth of ovarian cancer cells and reverse chemoresistant properties acquired from metastatic omentum.
    Int J Gynaecol Obstet. 2019 Mar 3. doi: 10.1002/ijgo.12800.
    PubMed     Text format     Abstract available

    Int J Oncol

  10. TAE IH, Park EY, Dey P, Son JY, et al
    Novel SIRT1 inhibitor 15-deoxy-Delta12,14-prostaglandin J2 and its derivatives exhibit anticancer activity through apoptotic or autophagic cell death pathways in SKOV3 cells.
    Int J Oncol. 2018;53:2518-2530.
    PubMed     Text format     Abstract available


  11. OZES AR, Pulliam N, Ertosun MG, Yilmaz O, et al
    Protein kinase A-mediated phosphorylation regulates STAT3 activation and oncogenic EZH2 activity.
    Oncogene. 2018;37:3589-3600.
    PubMed     Text format     Abstract available

    Oncol Rep

  12. MALENTACCHI F, Turrini I, Sorbi F, Projetto E, et al
    Pilot investigation of the mutation profile of PIK3CA/PTEN genes (PI3K pathway) in grade 3 endometrial cancer.
    Oncol Rep. 2019;41:1560-1574.
    PubMed     Text format     Abstract available

    PLoS Genet

  13. CLINE MS, Liao RG, Parsons MT, Paten B, et al
    BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2.
    PLoS Genet. 2018;14:e1007752.
    PubMed     Text format     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.